NDAINTRAVITREALIMPLANT
Approved
Oct 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
17
Data completeness
6/8 — Strong
YUTIQ (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. Approved for diabetic macular edema, non-infectious posterior uveitis, uveitis. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUTIQ is a fluocinolone acetonide intravitreal implant, a corticosteroid that works by binding corticosteroid hormone receptors to suppress ocular inflammation. It is approved for diabetic macular edema, non-infectious posterior uveitis, retinal vein occlusion, and related macular and retinal conditions. The implant delivers sustained corticosteroid activity directly to the posterior segment of the eye.
$0.201MPart D
LOE Approaching1.7 years to LOEProduct approaches loss of exclusivity in January 2028 with modest Part D utilization, signaling a lean commercial infrastructure focused on preservation and specialty positioning rather than growth.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (3)
Worked on YUTIQ at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.